The OlympiAD trial, which was the global phase 3 trial for metastatic HER2-negative breast cancer with germline BRCA1 or BRCA2 mutations, confirmed that olaparib increased PFS by 2.8 months to 7.0 months (hazard ratio 0.58; P<0.001) and received FDA approval [9]. Here, BRCA2 is linked to breast carcinoma.